Payment overview · 2025
General Payments
$1,057.59
51 reported records · 19 companies
Healthcare provider profile · identity verified
Mary E Mckinley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MACON, GA · NPI 1023003993
Verified facts
What the public records show
CMS Open Payments records show Mary E Mckinley, MD received $1,057.59 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Nexletol, Ozempic, Qulipta, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 787 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.60 | 22.7% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $238.22 | 22.5% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.61 | 8.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.66 | 5.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $60.68 | 5.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.51 | 5.7% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $57.73 | 5.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.56 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.65 | 2.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.07 | 2.8% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.47 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.28 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.79 | 1.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.29 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.01 | 1.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.56 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.12 | 1.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.55 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,057.59 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $209.43 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $104.97 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.88 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.61 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $82.09 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $61.66 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $60.68 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.51 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.63 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $57.73 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.56 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.07 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 787 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 299 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 173 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 251 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
299 | 67 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
299 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
173 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
124 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
251 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
787 | 87 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2174 | 356 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2168 | 282 |
| Amlodipine Besylate | Amlodipine Besylate | 1981 | 367 |
| Furosemide | Furosemide | 1696 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1571 | 335 |
| Gabapentin | Gabapentin | 1514 | 227 |
| Famotidine | Famotidine | 1453 | 142 |
| Omeprazole | Omeprazole | 1430 | 208 |
| Lisinopril | Lisinopril | 1209 | 203 |
| Potassium Chloride | Potassium Chloride | 1136 | 114 |
| Losartan Potassium | Losartan Potassium | 1059 | 233 |
| Trazodone Hcl | Trazodone Hcl | 1022 | 139 |
| Sertraline Hcl | Sertraline Hcl | 970 | 105 |
| Carvedilol | Carvedilol | 890 | 106 |
| Metoprolol Tartrate | Metoprolol Tartrate | 863 | 107 |
| Clopidogrel | Clopidogrel Bisulfate | 793 | 110 |
| Eliquis | Apixaban | 787 | 87 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 724 | 120 |
| Donepezil Hcl | Donepezil Hcl | 716 | 88 |
| Escitalopram Oxalate | Escitalopram Oxalate | 680 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 673 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 639 | 145 |
| Memantine Hcl | Memantine Hcl | 607 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 560 | 122 |
| Alprazolam | Alprazolam | 544 | 93 |
| Metformin Hcl | Metformin Hcl | 530 | 125 |
| Buspirone Hcl | Buspirone Hcl | 507 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 496 | 75 |
| Spironolactone | Spironolactone | 447 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 436 | 69 |
| Citalopram Hbr | Citalopram Hydrobromide | 434 | 73 |
| Tramadol Hcl | Tramadol Hcl | 426 | 115 |
| Simvastatin | Simvastatin | 418 | 114 |
| Duloxetine Hcl | Duloxetine Hcl | 393 | 46 |
| Montelukast Sodium | Montelukast Sodium | 391 | 74 |
| Mirtazapine | Mirtazapine | 377 | 57 |
| Bupropion Xl | Bupropion Hcl | 340 | 53 |
| Allopurinol | Allopurinol | 335 | 47 |
| Divalproex Sodium | Divalproex Sodium | 334 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 321 | 119 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 305 | 95 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 302 | 64 |
| Glimepiride | Glimepiride | 302 | 75 |
| Jardiance | Empagliflozin | 299 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 292 | 65 |
| Ezetimibe | Ezetimibe | 272 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 262 | 38 |
| Levetiracetam | Levetiracetam | 258 | 29 |
| Ozempic | Semaglutide | 251 | 51 |
| Sucralfate | Sucralfate | 250 | 36 |
| Atenolol | Atenolol | 249 | 33 |
| Midodrine Hcl | Midodrine Hcl | 249 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 244 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 237 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 224 | 55 |
| Aripiprazole | Aripiprazole | 223 | 19 |
| Celecoxib | Celecoxib | 222 | 39 |
| Myrbetriq | Mirabegron | 222 | 23 |
| Meloxicam | Meloxicam | 220 | 66 |
| Prednisone | Prednisone | 218 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 214 | 25 |
| Metformin Hcl Er | Metformin Hcl | 210 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 209 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 207 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 196 | 46 |
| Fenofibrate | Fenofibrate | 194 | 40 |
| Glipizide | Glipizide | 185 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 185 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 184 | 13 |
| Propranolol Hcl | Propranolol Hcl | 183 | 12 |
| Mounjaro | Tirzepatide | 173 | 31 |
| Xarelto | Rivaroxaban | 173 | 21 |
| Clonidine Hcl | Clonidine Hcl | 169 | 54 |
| Baclofen | Baclofen | 168 | 24 |
| Entresto | Sacubitril/Valsartan | 165 | 19 |
| Januvia | Sitagliptin Phosphate | 158 | 29 |
| Risperidone | Risperidone | 158 | 16 |
| Bumetanide | Bumetanide | 156 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 154 | 31 |
| Valsartan | Valsartan | 153 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 29 |
| Glipizide Er | Glipizide | 144 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 140 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 138 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 138 | 35 |
| Lorazepam | Lorazepam | 136 | 31 |
| Fenofibrate | Fenofibrate,micronized | 134 | 39 |
| Finasteride | Finasteride | 134 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 131 | 51 |
| Farxiga | Dapagliflozin Propanediol | 128 | 30 |
| Trulicity | Dulaglutide | 124 | 17 |
| Synthroid | Levothyroxine Sodium | 118 | 36 |
| Meclizine Hcl | Meclizine Hcl | 116 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 114 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 113 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 112 | 61 |
| Alendronate Sodium | Alendronate Sodium | 110 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 104 | 20 |
| Lamotrigine | Lamotrigine | 101 | suppressed |
| Clonazepam | Clonazepam | 99 | 18 |
| Ondansetron Odt | Ondansetron | 99 | 31 |
| Lovastatin | Lovastatin | 96 | suppressed |
| Fluconazole | Fluconazole | 94 | 58 |
| Dexlansoprazole Dr | Dexlansoprazole | 91 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 41 |
| Latanoprost | Latanoprost | 91 | 16 |
| Pregabalin | Pregabalin | 89 | 34 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 88 | 24 |
| Methylprednisolone | Methylprednisolone | 88 | 80 |
| Sotalol | Sotalol Hcl | 88 | suppressed |
| Nifedipine Er | Nifedipine | 84 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 84 | 52 |
| Cholestyramine | Cholestyramine (With Sugar) | 80 | 19 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 80 | suppressed |
| Lactulose | Lactulose | 79 | 27 |
| Novolog Flexpen | Insulin Aspart | 79 | 17 |
| Primidone | Primidone | 78 | 12 |
| Valacyclovir | Valacyclovir Hcl | 78 | 31 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | suppressed |
| Vascepa | Icosapent Ethyl | 76 | 19 |
| Nystatin | Nystatin | 75 | 46 |
| Verapamil Er | Verapamil Hcl | 75 | 12 |
| Linzess | Linaclotide | 74 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 73 | 17 |
| Azelastine Hcl | Azelastine Hcl | 72 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 18 |
| Methocarbamol | Methocarbamol | 71 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 70 | suppressed |
| Colchicine | Colchicine | 69 | 11 |
| Prazosin Hcl | Prazosin Hcl | 69 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | suppressed |
| Estradiol | Estradiol | 68 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 63 |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 13 |
| Flecainide Acetate | Flecainide Acetate | 65 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | suppressed |
| Gemtesa | Vibegron | 64 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 63 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 63 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 59 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 59 | suppressed |
| Belsomra | Suvorexant | 58 | 15 |
| Diazepam | Diazepam | 58 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 15 |
| Memantine Hcl Er | Memantine Hcl | 57 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | 13 |
| Cephalexin | Cephalexin | 56 | 52 |
| Azithromycin | Azithromycin | 55 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 53 | 11 |
| Benazepril Hcl | Benazepril Hcl | 53 | 11 |
| Lidocaine | Lidocaine | 52 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 52 | 12 |
| Zenpep | Lipase/Protease/Amylase | 52 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 51 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 14 |
| Ibuprofen | Ibuprofen | 51 | 18 |
| Klor-Con M20 | Potassium Chloride | 51 | 15 |
| Bethanechol Chloride | Bethanechol Chloride | 49 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 49 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 49 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 42 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 11 |
| Warfarin Sodium | Warfarin Sodium | 49 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | suppressed |
| Metolazone | Metolazone | 47 | 11 |
| Topiramate | Topiramate | 47 | suppressed |
| Pindolol | Pindolol | 46 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 45 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 45 | 13 |
| Enulose | Lactulose | 44 | 11 |
| Glycopyrrolate | Glycopyrrolate | 44 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 44 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Amantadine | Amantadine Hcl | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | 13 |
| Eszopiclone | Eszopiclone | 41 | 17 |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 30 |
| Bupropion Hcl | Bupropion Hcl | 40 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 40 | suppressed |
| Levemir Flexpen | Insulin Detemir | 40 | 16 |
| Mupirocin | Mupirocin | 40 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Irbesartan | Irbesartan | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Rybelsus | Semaglutide | 37 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 36 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Levemir | Insulin Detemir | 33 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Brilinta | Ticagrelor | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Dayvigo | Lemborexant | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Nystop | Nystatin | 30 | 14 |
| Pentoxifylline | Pentoxifylline | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Niacin Er | Niacin | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 16 |
| Ketoconazole | Ketoconazole | 27 | 13 |
| Repatha Syringe | Evolocumab | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 18 |
| Ibu | Ibuprofen | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 21 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Scopolamine | Scopolamine | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 11 |
| Fentanyl | Fentanyl | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Klor-Con M15 | Potassium Chloride | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bicalutamide | Bicalutamide | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Qulipta | Atogepant | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,057.59 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE, GEMTESA, JARDIANCE, JATENZO, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, TZIELD, Tymlos, UBRELVY, VRAYLAR, XIFAXAN | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error